Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

(2017) T E Witzig et al.   Blood Cancer Journal

Immune checkpoint blockade in lymphoid malignancies

(2016) Gita Thanarajasingam et al.   FEBS Journal

Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine

(2016) Minmin Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance

(2016) M M Patnaik et al.   Blood Cancer Journal

Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial

(2016) Patrick B Johnston et al.   Lancet Haematology

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

(2015) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Loss ofTET2in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis

(2015) Kasper D. Rasmussen et al.   GENES & DEVELOPMENT

Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

(2015) John G. Gribben et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of DNA methylation in renal cell carcinoma

(2015) Niraj Shenoy et al.   Journal of Hematology & Oncology

TET proteins and the control of cytosine demethylation in cancer

(2015) Laurianne Scourzic et al.   Genome Medicine

Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival

(2014) C. Y. Hu et al.   CLINICAL CANCER RESEARCH

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy

(2014) Y. Ma et al.   Science Translational Medicine

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

(2013) O. Odejide et al.   BLOOD

SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma

(2013) Eric Letouzé et al.   CANCER CELL

Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer

(2013) Christopher M. Stephenson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals

(2013) Ruichuan Yin et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Origins of aberrant DNA methylation in acute myeloid leukemia

(2013) T Schoofs et al.   LEUKEMIA

Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells

(2013) Kathryn Blaschke et al.   NATURE

Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

(2013) T. Clozel et al.   Cancer Discovery

Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity

(2013) Subhajyoti De et al.   PLoS Genetics

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

(2012) F. Lemonnier et al.   BLOOD

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer

(2012) Daniel A. Monti et al.   PLoS One

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Epigenetic Changes in the Myelodysplastic Syndrome

(2010) Jean-Pierre Issa   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects

(2009) Julien Verrax et al.   FREE RADICAL BIOLOGY AND MEDICINE

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

(2008) L. J. Hoffer et al.   ANNALS OF ONCOLOGY

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

(2008) Q. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA